AstraZeneca acquires Amplimmune for $225M upfront and milestones bringing the deal to a possible $500 M total. The asset is being acquired to complement its MedImmune business. Amplimmune has its AMP-514 ready for an IND filing and several other preclinical programs in the pipeline. AZ is looking for projects in its biological portfolio and hopes to make some of these pay off.
Amplimmune's claims to potential success involve its IMT-C platform which it is applying to various cancer therapeutic areas. Its technology is meant to activate the immune system to attack cancers. Like MedImmune, it too is based in Gaithersburg, MD -- which should make the commute short to collaborate between the two AZ assets. Plus, Amplimmune's CEO was formerly at MedImmune -- thus no surprises. MedImmune can now look at using the IMT-C platform to create combo therapies with its own pipeline candidates for cancer. Again, we will need to see if the synergies actually pan out. See Fierce Biotech.
Posted by Bruce Lehr Aug 26th 2013.